{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '5', 'STUDY OBJECTIVES', '5.1', 'PRIMARY', 'To evaluate the efficacy, safety and tolerability of alemtuzumab (IV) in paediatric patients', 'from 10 to <18 years of age with RRMS who have disease activity on prior DMT.', '5.2', 'SECONDARY', 'To assess the pharmacokinetics (PK), pharmacodynamics (PD), antidrug antibody (ADA)', 'formation, and potential effects of alemtuzumab on other MS disease characteristics such', 'as cognition and quality of life.', 'Property of the Sanofi Group - strictly confidential', 'Page 37', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '6', 'STUDY DESIGN', '6.1', 'DESCRIPTION OF THE STUDY', 'This is an open-label, rater-blinded, single-arm, before and after switch study of efficacy, safety', 'and tolerability of alemtuzumab in paediatric patients from 10 to <18 years of age with RRMS', 'with disease activity on prior DMT.', 'The study will consist of:', 'Screening period (0-28 days prior to M-4) - Patients and parents will receive information', 'on the study and on alemtuzumab. Inclusion/exclusion criteria will be reviewed. After', 'informed consent signature, screening assessments for eligibility will be performed.', 'Screening assessments may require more than one visit within the screening period which', 'may last a maximum of 28 days.', 'Prior DMT phase (approximately 4 months): M-4 to M0', '-', 'Eligibility confirmation visit: At the end of the screening period (at M-4)', 'patients/parents will come to the site to confirm patient is eligible for the study.', 'Investigator will check that all assessment allow patient inclusion. During this visit', 'patients will be reminded to continue their prior DMT (limited to interferon or GA', 'only).', '-', 'From M-4 visit to D-14 to D-7: Phone calls (approximately every month) will be', 'done, to remind patients to continue on their DMT and check patient status.', '-', 'Day -14 to D-7 visit: Investigator will confirm patient is eligible for alemtuzumab', 'administration and will tell the patient to discontinue current DMT 7 days prior to', 'administration of first dose of alemtuzumab at Month 0.', 'Alemtuzumab treatment phase (approximately 2 years) - This phase starts with', 'administration of first dose of alemtuzumab at M0, after discontinuation of current DMT,', 'and ends at M24. The second dose of alemtuzumab will be administered at M12. The MRI', 'based primary efficacy endpoint will be assessed over a 4 month period during this phase', 'compared to an equal period during the prior DMT phase.', 'Note: end of treatment phase (EOTP) refers to the end of the alemtuzumab treatment phase', '(see graphic study design [Section 1.1]).', 'Safety monitoring phase (approximately 3 years) - Additional safety follow-up and', 'monitoring for all patients treated with alemtuzumab will be conducted during this phase', 'to yield a total of 5 years of follow-up since first alemtuzumab treatment, including 4 years', 'post last treatment with alemtuzumab.', 'Note: end of study (EOS) refers to the end of the safety monitoring phase (see graphic', 'study design [Section 1.1]).', 'Property of the Sanofi Group - strictly confidential', 'Page 38', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'In addition, and for the primary endpoint assessment, two periods have been defined:', 'Period 1: will occur from M-4 up to MO. A baseline MRI will be performed close to M-4', 'during the screening period and another at Visit 3. Both MRI will be taken while patients', 'are on their prior DMT. It is important to ensure that these 2 MRI assessments are', 'performed 4 months (7 days) apart.', 'Period 2: will occur from M4 to M8: The MRI performed at the M4 visit will be the', 'baseline MRI for Period 2. A second MRI will be performed after alemtuzumab first', 'course of treatment at M8. It is important to ensure that these 2 MRI assessments are', 'performed 4 months (7 days) apart.', 'These two periods will be compared for the primary endpoint analysis.', '6.2', 'DURATION OF STUDY PARTICIPATION', '6.2.1 Duration of study participation for each patient', 'The maximum study duration per patient will be approximately 5 years and 5 months:', 'Screening period: 0-28 days prior to M-4 from signed informed consent to eligibility', 'confirmation.', 'Prior DMT phase: approximately 4 months from signed informed consent and screening', 'qualification to prior DMT discontinuation. Alemtuzumab treatment phase:', 'approximately 2 years, from first dose alemtuzumab administration to one year after last', 'dose of alemtuzumab administration.', 'Safety monitoring phase: approximately 3 years to complete the 48 months safety', 'follow-up post last treatment with alemtuzumab.', '6.2.2 Determination of end of clinical trial (all patients)', 'The EOS is defined as being the \"last patient last visit\" planned with the protocol. The last patient', 'visit will be considered when the last patient has completed safety monitoring phase (M60).', 'The Sponsor reserves the right to discontinue the study at any time.', '6.3', 'INTERIM ANALYSIS', 'A partial database lock will be done after the last patient has completed efficacy assessments', 'including MRI at the end of Period 2. This database lock will allow comparing lesion counts', 'between Period 1 (M-4 to M0) and Period 2 (M4-M8). No formal interim analysis will be', 'performed.', 'Property of the Sanofi Group - strictly confidential', 'Page 39', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}